 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
A friend of mine, Shahram Mori, recently pointed to this issue -- as a way to play trickle down from recent sector liquidity. Current market cap is $43 million. Tuesday February 15, 9:22 am Eastern Time Company Press Release SOURCE: DGI BioTechnologies, LLC. DGI BioTechnologies, LLC., Makes Key Additions to Scientific Team EDISON, N.J., Feb. 15 /PRNewswire/ -- DGI BioTechnologies, LLC. (DGI), which is majority owned by New Brunswick Scientific Co., Inc. (Nasdaq: NBSC - news), today announced that it has made the following key additions to its core scientific team: Director of Protein Technologies-Michael Lennick, Ph.D. Director of Molecular Biology-Neil I. Goldstein, Ph.D. Group Leader of High-Throughput Screening (HTS)-Paul W. Fletcher, Ph.D. Dr. Lennick, 47, is a protein biochemist with over 20 years' experience in research and development, specializing in monoclonal antibodies, vaccines, recombinant proteins and human blood products, complemented by a background in immunochemistry and assay development. Most recently, he was Assistant Director in Charge of Pharmaceutical Processing for Medarex Corporation in Clinton, New Jersey. Dr. Lennick earned his Ph.D. in Biology from Wesleyan University in 1982 and was a postdoctoral fellow with the American Red Cross in Bethesda, Maryland, from 1982 to 1984. Dr. Goldstein, 51, well versed in all aspects of immunology, molecular biology, biochemistry, and cell biology, joined DGI from GenQuest, Inc., New York, New York, where he was Vice President and Director of Molecular and Cell Biology. Dr. Goldstein received his Ph.D. in Microbiology from Rutgers University in 1975 and was a postdoctoral fellow, The Waksman Institute of Microbiology at Rutgers University (1975-76); and The Wistar Institute (1976- 78). Dr. Fletcher, 48, is a biochemical pharmacologist with over 20 years of experience in research and development, specializing in receptor biochemistry, signal transduction and assay development. Before joining DGI, he served as Manager of Pharmacology and as a Program Manager in Wound Healing for ProCyte Corporation in Redmond, Washington. Dr. Fletcher attended the University of Wyoming (1975-78) where he received his Ph.D. in Biochemistry and Reproductive Physiology, and was an NIH postdoctoral fellow, Biochemical Endocrinology, (1978-80) at Colorado State University. DGI President and Chief Executive Officer Dr. Arthur J. Blume said: ''With DGI poised to become an integral part of future drug discoveries, one of our many objectives is the establishment of a comprehensive infrastructure to support strategic growth.'' He continued, ''Dr. Lennick's expertise gives DGI the ability to obtain sufficient, often difficult-to-make quantities of drug targets needed for HTS. Dr. Goldstein brings master skills with nucleic acids required for the generation and use of our surrogate libraries. These libraries are utilized in target validation and selection and providing the surrogates needed for DGI's site directed assays (SDAs). Dr. Fletcher's extensive background in molecular pharmacology provides DGI the guidance required to build, validate and run its SDAs on today's leading-edge HTS equipment, and to oversee the database management vital to identifying good drug-discovery leads. ''The additions of Drs. Lennick, Goldstein and Fletcher, by virtue of their unique knowledge and extensive experience, further broaden our capabilities and strengthen our organization as we continue to evolve,'' he concluded. DGI BioTechnologies, LLC., majority owned by New Brunswick Scientific Co., Inc., has developed a proprietary process that offers pharmaceutical and biotechnology companies an improved method of identifying novel, small molecule, orally available drug leads. This press release includes statements that may constitute forward-looking statements made pursuant to the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995. This information may involve risks and uncertainties, including without limitation, risks relating to the development by DGI of its technology, that could cause actual results to differ materially from the forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. SOURCE: DGI BioTechnologies, LLC. | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |